Keywords: GlaxoSmithKline, Avandia, Cardiovascular risks, EMEA, FDA
European Medicines Agency starts review of rosiglitazone-containing medicines, as FDA releases briefing documents; EMEA reviews way forward for the Agency
Article | 12 July 2010
The European Medicines Agency (EMEA) said last Friday that it has started a review of the rosiglitazone-containing anti-diabetes medicines Avandia ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
